# Clinical Cases: Drug Development and Toxicology ## Case 1: Acetaminophen Overdose - Using the Rumack-Matthew Nomogram ### Patient Demographics - **Age:** 22 years - **Sex:** Female - **Occupation:** College student ### Chief Complaint "I took a bunch of pills a few hours ago." ### History of Present Illness A 22-year-old woman is brought to the emergency department by her roommate after admitting she ingested "a handful" of acetaminophen tablets following an argument with her boyfriend approximately 4 hours ago. She reports taking "about 30 pills" of Extra Strength Tylenol (500 mg each) in a single ingestion. She now has mild nausea and abdominal discomfort but otherwise feels okay. She denies co-ingestion of other substances, alcohol, or other medications. She has no suicidal ideation currently and expresses regret. Her roommate found her with an empty bottle that originally contained 50 tablets. ### Estimated Ingestion - 30 tablets x 500 mg = **15,000 mg (15 g) of acetaminophen** - Patient weight: 60 kg - Dose: **250 mg/kg** (significantly above toxic threshold of 150 mg/kg) ### Past Medical History - Depression (not currently on medications) - No liver disease - No chronic acetaminophen use - No alcohol use disorder ### Physical Examination (4 Hours Post-Ingestion) - **Vital Signs:** BP 118/72 mmHg, HR 82 bpm, RR 16/min, T 37.1C, O2 sat 99% RA - **General:** Alert, anxious, no acute distress - **HEENT:** Normal - **Cardiovascular:** Regular rhythm - **Abdomen:** Soft, mild RUQ tenderness, no hepatomegaly - **Neurologic:** Alert, oriented, no asterixis - **Skin:** No jaundice ### Laboratory Workup **Initial Labs (4 hours post-ingestion):** | Test | Result | Reference | Interpretation | |------|--------|-----------|----------------| | **Acetaminophen level** | **185 mcg/mL** | Therapeutic: 10-20 | **Toxic** | | AST | 32 U/L | 10-40 | Normal | | ALT | 28 U/L | 7-56 | Normal | | Total Bilirubin | 0.8 mg/dL | 0.1-1.2 | Normal | | INR | 1.0 | 0.8-1.2 | Normal | | Creatinine | 0.8 mg/dL | 0.6-1.2 | Normal | | pH | 7.42 | 7.35-7.45 | Normal | | Lactate | 1.2 mmol/L | 0.5-2.2 | Normal | | Salicylate level | < 1 mg/dL | - | Negative | | Ethanol level | < 10 mg/dL | - | Negative | | Urine drug screen | Negative | - | - | ### Using the Rumack-Matthew Nomogram **The Rumack-Matthew Nomogram:** - Used for SINGLE acute acetaminophen ingestions with KNOWN time of ingestion - Plots serum acetaminophen concentration against time post-ingestion - Determines need for N-acetylcysteine (NAC) treatment **Key Treatment Lines:** | Line | 4-hour level | Risk | |------|--------------|------| | Original Rumack-Matthew | 200 mcg/mL | "Probable hepatotoxicity" | | **Treatment Line (US)** | **150 mcg/mL** | Start NAC if above this line | | Modified (high-risk) | 100 mcg/mL | Used for high-risk patients | **This Patient:** - Time: 4 hours post-ingestion - Level: 185 mcg/mL - **ABOVE the treatment line (150 mcg/mL at 4 hours)** - **NAC treatment is indicated** **Nomogram Interpretation:** ``` Acetaminophen Concentration (mcg/mL) 500 | | Probable |___ Toxicity 200 | \___ (Rumack-Matthew line) | \___ Treatment 150 |___ \___ Line | \___ "Treatment line" 100 | \___ | \___ 50 | \___ |___________________\____ 0 4 8 12 16 20 24 Hours Post-Ingestion ``` ### Pathophysiology of Acetaminophen Toxicity **Normal Metabolism:** - Acetaminophen predominantly metabolized by glucuronidation (60%) and sulfation (35%) - Small amount (5%) oxidized by CYP2E1 to **NAPQI** (N-acetyl-p-benzoquinone imine) - NAPQI is highly reactive but immediately conjugated with **glutathione** to non-toxic metabolite **In Overdose:** 1. Glucuronidation and sulfation pathways become saturated 2. More acetaminophen shunted to CYP2E1 pathway 3. Increased NAPQI production 4. **Glutathione stores depleted** (when < 30% of normal) 5. Unconjugated NAPQI binds to hepatocyte proteins 6. Cellular damage, oxidative stress, and hepatocyte death 7. Centrilobular necrosis (Zone 3 - highest CYP concentration) **Stages of Acetaminophen Toxicity:** | Stage | Time | Clinical Findings | Labs | |-------|------|-------------------|------| | I | 0-24 h | Nausea, vomiting, malaise, or asymptomatic | Normal or mildly elevated AST/ALT | | II | 24-72 h | RUQ pain, hepatomegaly | **Rising AST/ALT**, PT prolonged | | III | 72-96 h | Peak hepatotoxicity, possible hepatic failure | **AST/ALT peak** (can exceed 10,000), coagulopathy, encephalopathy | | IV | 4 d - 2 wk | Recovery or death | Resolution or transplant | **This patient is in Stage I** - she feels relatively well but is at high risk for progression ### Treatment **N-ACETYLCYSTEINE (NAC) - The Antidote** **Mechanism of NAC:** 1. **Replenishes glutathione:** NAC is metabolized to cysteine, a glutathione precursor 2. **Direct NAPQI detoxification:** Can directly conjugate with NAPQI 3. **Antioxidant effects:** Scavenges free radicals, reduces oxidative stress 4. **Hepatoprotective:** Improves microcirculation, may support hepatocyte regeneration **Key Timing:** - **Most effective within 8 hours** of ingestion (near 100% protection) - Still beneficial up to 24 hours - Provides benefit even after hepatotoxicity established **NAC Protocols:** **IV Protocol (Preferred in most EDs):** | Bag | Dose | Duration | |-----|------|----------| | Loading | 150 mg/kg in 200 mL D5W | 1 hour | | Bag 2 | 50 mg/kg in 500 mL D5W | 4 hours | | Bag 3 | 100 mg/kg in 1000 mL D5W | 16 hours | | **Total** | **300 mg/kg** | **21 hours** | **Oral Protocol (Alternative):** - Loading: 140 mg/kg - Maintenance: 70 mg/kg every 4 hours x 17 doses - Total duration: 72 hours **This Patient's Treatment:** - Initiated IV NAC within 4.5 hours of ingestion (excellent timing) - 21-hour protocol **Anaphylactoid Reaction to IV NAC:** - Occurs in 10-20% of patients - Flushing, pruritus, urticaria, bronchospasm - NOT true IgE-mediated allergy - Usually occurs during loading dose - Management: Slow infusion rate, antihistamines; rarely need to stop ### Additional Management **1. GI Decontamination:** - **Activated charcoal** if < 4 hours post-ingestion (she's at 4 hours - borderline) - Dose: 1 g/kg (max 50 g) - Binds acetaminophen, reduces absorption - Administered in this case (just within window) **2. Supportive Care:** - IV fluids - Antiemetics for nausea - Monitor for complications **3. Laboratory Monitoring:** - Serial AST, ALT, INR, creatinine every 6-12 hours - Monitor for hepatotoxicity development - Peak transaminases expected 48-72 hours if toxicity occurs **4. Psychiatry Consultation:** - Required for intentional ingestion - Safety assessment before discharge ### Clinical Course - Completed 21-hour IV NAC protocol - Repeat labs at 12 hours: AST 45, ALT 52, INR 1.0 (minimal elevation) - Repeat labs at 24 hours: AST 38, ALT 45, INR 1.0 (normalizing) - No evidence of hepatotoxicity - Psychiatry cleared for discharge with outpatient follow-up - Discharged day 2 ### When Nomogram Cannot Be Used **Limitations of Rumack-Matthew Nomogram:** - Unknown or unreliable time of ingestion - Repeated supratherapeutic ingestions (chronic) - Extended-release acetaminophen (delayed peak) - Co-ingestion slowing GI motility - Presentation > 24 hours post-ingestion **In These Cases:** - Start NAC empirically if concern for significant ingestion - Use clinical judgment and serial transaminases - Toxicology consultation recommended ### Clinical Pearl The Rumack-Matthew nomogram is a critical tool for acute single-ingestion acetaminophen overdose but requires accurate timing. NAC is nearly 100% effective in preventing hepatotoxicity when given within 8 hours of ingestion. The mechanism of acetaminophen toxicity involves depletion of glutathione and accumulation of the toxic metabolite NAPQI. NAC works by replenishing glutathione stores and directly conjugating NAPQI. Even patients who present late or develop hepatotoxicity benefit from NAC. Activated charcoal should be given if within 4 hours of ingestion. All intentional overdoses require psychiatric evaluation. ### Clinical Image ![Centrilobular Necrosis](case_01_image.jpg) *Liver histopathology demonstrating centrilobular necrosis (Zone 3) characteristic of acetaminophen hepatotoxicity. Zone 3 hepatocytes surrounding the central vein have the highest concentration of CYP450 enzymes that generate the toxic metabolite NAPQI.* **Image Source:** Wikimedia Commons - "Centrilobular necrosis liver" **License:** CC BY-SA 3.0 **URL:** https://commons.wikimedia.org/wiki/File:Centrilobular_necrosis.jpg --- ## Case 2: Serotonin Syndrome - Drug Interaction Toxicity ### Patient Demographics - **Age:** 34 years - **Sex:** Male - **Occupation:** Software developer ### Chief Complaint "He's shaking uncontrollably and sweating through his clothes." ### History of Present Illness A 34-year-old man is brought to the emergency department by his wife after she found him at home confused, trembling, and drenched in sweat. He has a history of depression treated with sertraline 100 mg daily for 2 years. Three days ago, he saw a new primary care physician for back pain and was prescribed tramadol 50 mg every 6 hours. Today, he also took St. John's Wort (herbal supplement) that he purchased to "help with his mood" as he had been feeling more depressed. Within hours of taking the St. John's Wort, he developed tremor, agitation, and profuse sweating. His wife notes his symptoms have been rapidly worsening over the past 2 hours. ### Medications and Supplements - **Sertraline 100 mg daily** (SSRI - selective serotonin reuptake inhibitor) - **Tramadol 50 mg q6h** (opioid with serotonin reuptake inhibition, started 3 days ago) - **St. John's Wort** (herbal - induces serotonin release, taken today) ### Physical Examination - **Vital Signs:** T 39.2C (102.6F), HR 128 bpm, BP 162/98 mmHg, RR 24/min - **General:** Diaphoretic, agitated, restless, cannot lie still - **HEENT:** Pupils 6 mm bilaterally, reactive; dry mucous membranes - **Neurologic:** - Mental status: Agitated, confused, disoriented - **Tremor:** Generalized, coarse - **Clonus:** **Inducible clonus at ankles bilaterally** (>3 beats) - **Hyperreflexia:** 3+ reflexes throughout - **Muscle rigidity:** Increased tone, more prominent in lower extremities - **Skin:** Flushed, profusely diaphoretic - **Abdomen:** Hyperactive bowel sounds ### Diagnosis **Serotonin Syndrome** **Hunter Criteria for Serotonin Syndrome:** In the presence of a serotonergic agent, ONE of the following: 1. Spontaneous clonus 2. Inducible clonus + agitation or diaphoresis 3. Ocular clonus + agitation or diaphoresis 4. Tremor + hyperreflexia 5. Hypertonia + temperature >38C + ocular or inducible clonus **This Patient Meets Criteria:** - Serotonergic agents: Sertraline + Tramadol + St. John's Wort (triple hit) - Has: Inducible clonus + diaphoresis + agitation - Also has: Tremor + hyperreflexia - Also has: Temperature 39.2C + inducible clonus ### Pathophysiology of Serotonin Syndrome **Serotonin (5-HT) Excess in CNS and Periphery:** **Serotonergic Drug Mechanisms:** | Mechanism | Examples | |-----------|----------| | Increase serotonin synthesis | L-tryptophan | | Increase serotonin release | St. John's Wort, amphetamines, MDMA | | **Inhibit serotonin reuptake** | **SSRIs (sertraline)**, **SNRIs**, **tramadol**, TCAs, meperidine | | Inhibit serotonin metabolism | MAOIs, linezolid | | Direct serotonin receptor agonism | Triptans, buspirone, LSD | **This Patient's Triple Combination:** 1. **Sertraline:** Blocks serotonin reuptake (SERT inhibitor) 2. **Tramadol:** Blocks serotonin reuptake (in addition to opioid effect) 3. **St. John's Wort:** Multiple mechanisms - induces serotonin release, weak MAOI **Clinical Features by System:** | System | Manifestations | Mechanism | |--------|----------------|-----------| | **Neuromuscular** | Clonus, hyperreflexia, tremor, rigidity | 5-HT1A receptor activation in spinal cord | | **Autonomic** | Hyperthermia, diaphoresis, tachycardia, hypertension, mydriasis, diarrhea | Peripheral 5-HT effects + hypothalamic dysregulation | | **Mental Status** | Agitation, confusion, anxiety | CNS serotonin excess | ### Distinguishing Serotonin Syndrome from Neuroleptic Malignant Syndrome | Feature | Serotonin Syndrome | NMS | |---------|-------------------|-----| | **Onset** | **Rapid (hours)** | Gradual (days) | | Causative agent | Serotonergic drugs | Dopamine antagonists (antipsychotics) | | **Neuromuscular** | **Clonus, hyperreflexia** | "Lead-pipe" rigidity, bradyreflexia | | Tremor | Yes (often) | Less common | | **Clonus** | **Characteristic** | Absent | | Pupils | Dilated | Normal | | Bowel sounds | Hyperactive | Decreased | | Lab findings | Mild CK elevation | Markedly elevated CK | | **Resolution** | **Rapid (24-72h)** | Days to weeks | **Key Differentiator:** Clonus and hyperreflexia point to serotonin syndrome; "lead-pipe" rigidity and bradyreflexia point to NMS ### Treatment **1. DISCONTINUE ALL SEROTONERGIC AGENTS:** - Stop sertraline, tramadol, St. John's Wort immediately - Review medication list for any other serotonergic drugs **2. SUPPORTIVE CARE (Mainstay of Treatment):** - **IV fluids** for volume depletion from diaphoresis - **External cooling** for hyperthermia (cooling blankets, ice packs) - Avoid antipyretics (hyperthermia is from muscle activity, not hypothalamic setpoint) - **Benzodiazepines** for agitation and to reduce muscle hyperactivity: - Lorazepam 2 mg IV, repeat as needed - Also helps control autonomic instability **3. SEROTONIN ANTAGONIST (for moderate-severe cases):** - **Cyproheptadine:** - First-generation antihistamine with 5-HT2A antagonist activity - Loading dose: 12 mg PO/NG - Maintenance: 2 mg every 2 hours until symptoms improve, then 8 mg every 6 hours - Only available in oral form - Reserve for cases not responding to benzodiazepines and supportive care **4. AVOID:** - Physical restraints (can worsen hyperthermia from muscle activity) - Antipyretics (ineffective for muscular hyperthermia) - Succinylcholine if intubation needed (hyperkalemia risk from muscle rigidity) **5. SEVERE CASES:** - Intubation with non-depolarizing paralytic for refractory hyperthermia - ICU admission ### Clinical Course - Sertraline, tramadol, St. John's Wort discontinued - IV fluids administered - Lorazepam 2 mg IV x 3 doses with improvement in agitation - Cooling blankets applied; temperature decreased to 37.8C within 4 hours - Cyproheptadine 12 mg given via NG tube - Significant improvement within 12 hours - Clonus resolved by 24 hours - Transferred out of ICU on day 2 - Discharged day 3 with psychiatry follow-up for depression management ### Prevention and Patient Education **Key Drug Interactions to Avoid:** - SSRI/SNRI + tramadol - SSRI/SNRI + MAOIs (contraindicated; requires 2-week washout) - SSRI + St. John's Wort - SSRI + triptans (use with caution) - SSRI + linezolid (linezolid is a weak MAOI) - SSRI + meperidine - Multiple serotonergic agents concurrently **Patient Counseling:** - Inform ALL providers about antidepressant use - Check with pharmacist before starting any new medication or supplement - St. John's Wort has real pharmacologic activity and drug interactions - Know warning signs: confusion, tremor, sweating, muscle twitching - Seek immediate care if symptoms develop ### Clinical Pearl Serotonin syndrome is a potentially life-threatening drug-induced condition caused by excess serotonergic activity. The hallmark clinical findings are clonus (spontaneous or inducible) and hyperreflexia, which differentiate it from neuroleptic malignant syndrome. Onset is rapid (usually within hours) and correlates with starting, increasing, or adding a serotonergic drug. Treatment is primarily supportive: discontinue offending agents, benzodiazepines for agitation and muscle hyperactivity, and cooling for hyperthermia. Cyproheptadine is a specific 5-HT2A antagonist used in moderate-severe cases. Most patients recover fully within 24-72 hours once offending drugs are stopped. This case highlights the importance of drug interaction awareness - tramadol is often overlooked as a serotonergic agent, and many patients don't disclose herbal supplement use. ### Clinical Image ![Drug Interaction Warning](case_02_image.jpg) *Illustration depicting drug interaction awareness. The combination of multiple serotonergic agents, including SSRIs, opioids with serotonin activity (tramadol), and herbal supplements (St. John's Wort), can precipitate life-threatening serotonin syndrome.* **Image Source:** Wikimedia Commons - "Drug interactions" **License:** CC BY-SA 4.0 **URL:** https://commons.wikimedia.org/wiki/File:Drug_interactions.jpg ---